Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of Prophylactic Glycerin Suppositories for Feeding Intolerance in Very Low Birth Weight Preterm Infants: a Randomized Trial

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01799629
Recruitment Status : Recruiting
First Posted : February 27, 2013
Last Update Posted : September 2, 2020
Sponsor:
Collaborators:
Dr. Sulaiman Alhabib Medical City, Riyadh
Security Forces Hospital
Information provided by (Responsible Party):
Emad Mohammad Khadawardi, King Faisal Specialist Hospital & Research Center

Brief Summary:
To evaluate the efficacy of prophylactic glycerin suppositories will accelerate the elimination of meconium from the large intestine and thus reduce the incidence of feeding intolerance in very low birth weight (VLBW) infants

Condition or disease Intervention/treatment Phase
Infant, Very Low Birth Weight Drug: Glycerin suppositories Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 220 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Efficacy of Prophylactic Glycerin Suppositories for Feeding Intolerance in Very Low Birth Weight Preterm Infants: a Randomized Trial
Actual Study Start Date : March 2013
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : June 2022

Resource links provided by the National Library of Medicine

Drug Information available for: Glycerin

Arm Intervention/treatment
Experimental: Intervention
Intervention group will receive the glycerin suppository
Drug: Glycerin suppositories
No Intervention: Control
Normal care



Primary Outcome Measures :
  1. days to achieve full tolerated feeding (breast milk or formula) by NGT or by mouth (140cc/kg/day) [ Time Frame: 2years ]

Secondary Outcome Measures :
  1. Incidence of feeding intolerance [ Time Frame: 2years ]
    which is defined by the presence of GRVs > 50 % of the previous feed for two consecutive feeds in addition to two of the following: I. Abdominal distention > 1 cm in 12 hour. II. Abdominal tenderness. III. Vomiting. IV. Bile stained aspirate.

  2. Incidence of necrotizing enterocolitis (NEC) [ Time Frame: 2years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 1 Month   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Preterm infants with birth weight < 1250g.
  2. Inborn or outborn infants
  3. Less than 72 hours of age.

Exclusion Criteria:

  1. Congenital malformations.
  2. Acute abdomen needing surgical intervention.
  3. Severity of illness such that death is likely in the first few days after birth.
  4. Inability to get the parental consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01799629


Locations
Layout table for location information
Saudi Arabia
King Faisal Specialist Hospital & Research Centre Recruiting
Riyadh, Saudi Arabia, 11211
Contact: Eamd m Khadawardi, MD    00966505541843    ekhadawardi@kfshrc.edu.sa   
Principal Investigator: Emad M Khadawardi, MD         
Sub-Investigator: Eyad Almidani, MD         
Sub-Investigator: Khalid Al-Faleh, MD         
Sub-Investigator: Khalid Alhussain, MD         
Sub-Investigator: Jasim Anabrees, MD         
Security Forces Hospital Recruiting
Riyadh, Saudi Arabia
Contact: Khalid Alhussain, MD       kalhussein9@hotmail.com   
Sulaiman Al habib Medical Center Recruiting
Riyadh, Saudi Arabia
Contact: Jasim Anabrees, MD    00966590591102    jasim1800@yahoo.com   
Sub-Investigator: Jasim Anabrees, MD         
Sponsors and Collaborators
King Faisal Specialist Hospital & Research Center
Dr. Sulaiman Alhabib Medical City, Riyadh
Security Forces Hospital
Investigators
Layout table for investigator information
Principal Investigator: Emad M Khadawardi, MD King Faisal Specialist Hospital & Research Centre
Layout table for additonal information
Responsible Party: Emad Mohammad Khadawardi, Consultant Neonatology, King Faisal Specialist Hospital & Research Center
ClinicalTrials.gov Identifier: NCT01799629    
Other Study ID Numbers: 2121 110
First Posted: February 27, 2013    Key Record Dates
Last Update Posted: September 2, 2020
Last Verified: September 2020
Keywords provided by Emad Mohammad Khadawardi, King Faisal Specialist Hospital & Research Center:
Glycerin suppositories
Feeding intolerance
preterm infants
prophylactic use
elimination of meconium
Additional relevant MeSH terms:
Layout table for MeSH terms
Body Weight
Birth Weight
Glycerol
Cryoprotective Agents
Protective Agents
Physiological Effects of Drugs